Preventing dangerous blood clots after joint replacement surgery is one of the most consequential decisions in orthopedic medicine — and the optimal anticoagulation strategy has been debated for years. A trial published in the New England Journal of Medicine now adds meaningful clinical evidence to that debate, comparing a sequential anticoagulation approach against standard aspirin monotherapy in patients recovering from total hip or knee arthroplasty.
The study evaluated a stepped-down protocol in which patients initially received rivaroxaban — an oral factor Xa inhibitor — followed by a transition to aspirin, versus aspirin alone from the outset. The core question was whether the more potent early anticoagulation phase would reduce venous thromboembolism (VTE) events, including deep vein thrombosis and pulmonary embolism, without disproportionately increasing bleeding risk. The trial appears in NEJM Volume 395, though the excerpt available limits granular reporting of effect sizes, cohort demographics, and specific event rates.
This finding matters in a well-established clinical context: arthroplasty patients face peak VTE risk in the first two weeks post-surgery, precisely the window where rivaroxaban's mechanism — direct, reversible Xa inhibition — offers more consistent anticoagulation than aspirin's antiplatelet action. Aspirin has gained traction as a simpler, cheaper alternative, but its mechanism targets platelet aggregation rather than the coagulation cascade, leaving a theoretical gap in early VTE prevention. A sequential strategy attempts to capture the pharmacological strengths of both agents at the biologically appropriate time points. The clinical trade-off, however, is real: more aggressive anticoagulation carries elevated risk of major bleeding events, wound complications, and hematoma formation. Whether the NEJM trial demonstrates a net clinical benefit that justifies universal adoption of this two-drug sequence, or identifies patient subgroups most likely to benefit, is the key question readers should explore in the full publication. As a large randomized trial in a high-impact journal, this represents potentially practice-changing evidence for orthopedic and hematology teams.